ClinicalTrials.gg
CompletedNCT06355765Updated Apr 17, 2024

Citicoline & Antioxidants in Glaucoma

An observational study in Glaucoma, Open-Angle, sponsored by University of Naples. Completed at 1 site in Italy. Open to participants aged 30 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-04-17.

Sponsored by University of Naples · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
60
Ages
30 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Glaucoma, Open-Angle with a site in Italy — 1 open to participants now, 3 under way, 1 of them phase 3. Glaucoma, Open-Angle · Italy.

Enrollment
5th of 10
60 · median 59
Started
2022
with 2 others
Observational
10 of 35
1 open now
Registered
33rd of 35
by date

Among the 35 studies in Glaucoma, Open-Angle with a site in Italy, this one is the 5th largest by enrollment of the 10 observational ones that give a count, is one of 3 that started in 2022, is one of 10 observational ones, and was the 33rd registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

1 of the 35 studies in Glaucoma, Open-Angle with a site in Italy is open now. Recruiting first, the newest first:

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 30 Years to 90 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Glaucoma, Open-Angle with a site in Italy, or all of them as a file.
02

Study summary

To evaluate the long-term effects of oral citicoline, vitamins A, B, C and E, and blackcurrant therapy in patients with primary open-angle glaucoma (POAG) using optical coherence tomography (OCT), OCT angiography (OCTA) and microperimetry parameters.

Read the detailed description

AIMS: To evaluate the long-term effects of oral citicoline, vitamins A, B, C and E, and blackcurrant therapy in patients with primary open-angle glaucoma (POAG) using optical coherence tomography (OCT), OCT angiography (OCTA) and microperimetry parameters.

METHODS: Fifteen patients with POAG (treated group) received one soluble liquid sachet daily for 20 days a month of a complementary dietary supplement containing in fixed combination citicoline, vitamins A, B, C, and E, and blackcurrant for 1 year. Fifteen age-matched subjects affected by POAG were given a placebo and served as a control group. The patients underwent best corrected visual acuity (BCVA), Goldmann applanation tonometry, microperimetry examination, OCT, and OCTA at the beginning of the study and then at 1, 6 and 12 months.

03

Conditions studied

  • Glaucoma, Open-Angle

Browse trials for

04

Who can participate

Ages eligible
30 Years to 90 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

primary care clinic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of POAG
  • aged between 18 and 75 years
  • Patients with controlled intraocular pressure (IOP) below 20 mmHg, who had been on the same topical hypotensive therapy for at least 3 months
  • myopia less than 5 diopters (D) were considered eligible for inclusion.

Exclusion criteria

Exclusion Criteria:

  • IOP levels exceeding 21 mmHg,
  • hyper-sensitivity to citicoline,
  • a history of optic neuritis,
  • previous glaucoma or retinal surgery,
  • prior cataract or refractive surgery,
  • macular degeneration or other retinal disorders,
  • any systemic diseases that could potentially lead to neurodegeneration (e.g., multiple sclerosis, diabetes)
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
60 participants (actual)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Citicoline blackcurrant

    The treated group received a unique combination of oral dietary supplements, formulated in a soluble liquid sachet format for optimal absorption and convenience. This formulation included the following key components: citicoline (500 mg), vitamins A (300 μm), B group (4.415 mg), C (115 μm), and E (5 μm), and blackcurrant extract (50 mg). The participants in the treated group were instructed to take one sachet daily for 20 days each month, followed by a 10-day pause, and this therapy cycle was repeated throughout the 12-month follow-up period

    Dietary Supplement: Citicoline blackcurrant supplement

  • Placebo

    The treated group received a unique combination of oral placebo. The participants in the treated group were instructed to take one sachet daily for 20 days each month, followed by a 10-day pause, and this therapy cycle was repeated throughout the 12-month follow-up period

Interventions

  • Dietary supplementCiticoline blackcurrant supplement

    Citicoline, Vitamins A, B, C and E, and Blackcurrant

06

What researchers measure

Primary outcomes

  1. Evaluation of Ganglionar cells complex (GCC)

    evaluate the long-term effects of oral citicoline, vitamins A, B, C and E, and blackcurrant therapy in patients with primary open-angle glaucoma (POAG) on GCC using optical coherence tomography (OCT)

    Time frame: From enrollment to the end of treatment at 1 year

Secondary outcomes

  1. Evaluation of Retinal nerve fiber layer (RNFL)

    evaluate the long-term effects of oral citicoline, vitamins A, B, C and E, and blackcurrant therapy in patients with primary open-angle glaucoma (POAG) on RNFL using optical coherence tomography (OCT)

    Time frame: From enrollment to the end of treatment at 1 year

07

Study locations

1 site
  • University of Naples Federico II
    NAples, 80131, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Dec 2022, 11 months.

Of 53 observational studies under Glaucoma, Open-Angle, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2024
First posted
Apr 9, 2024
StartActual
Jan 10, 2022
Primary completionActual
Dec 10, 2022
CompletionActual
Dec 10, 2022
Last update
Apr 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06355765
Lead sponsor
University of Naples
Responsible party
Luca D'Andrea (Prinicipal investigator, University of Naples) — Principal investigator
First posted
Apr 9, 2024
Start date
Jan 10, 2022
Primary completion
Dec 10, 2022
Completion
Dec 10, 2022
Last update
Apr 17, 2024

Study contacts

Luca D'Andrea, MD
principal investigator · Federico II University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion